MedTrace Logo

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

NCT03196349 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-12-13

Study results available
· View outcomes & findings →

Summary

Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Warfarin

Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3

DRUG

Apixaban 2.5 MG

Will be randomized to receive open label apixaban of 2.5 mg twice daily

DRUG

Rivaroxaban 10 MG

Will be randomized to receive open label rivaroxaban of 10mg daily

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • Thomas Ortel, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-05-01
Completion
2019-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03196349 on ClinicalTrials.gov